Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.60 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.60 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211670 | 1.00 | PIM1 (0.60) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL14206408 | 1.00 | PIM1 (0.60) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL1271996 | 0.94 | CKS1B (0.55) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL4553425 | 0.93 | MAP4K4 (0.56) | PIM1PIM3PIM2CTSKPDE10A | |
| SCHEMBL13156657 | 0.93 | MAP4K4 (0.56) | PIM1PIM3PIM2CTSKPDE10A | |
| SCHEMBL13156648 | 0.93 | MAP4K4 (0.56) | PIM1PIM3PIM2CTSKPDE10A | |
| SCHEMBL14206788 | 0.89 | CKS1B (0.52) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL9984095 | 0.85 | PIM1 (0.48) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL17384450 | 0.85 | PIM1 (0.59) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL12283936 | 0.85 | PIM1 (0.67) | PIM1PIM3PIM2CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078003-B1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9206142-B2 | Anilinopiperazine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2078002-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| US-8227605-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | SCHERING CORPORATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055090-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | PIM1 1445/4885PIM3 1645/4885PIM2 906/4885 |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MAPK15, CDK15, MAPKAPK5 | PIM1 2719/4885PIM3 2561/4885PIM2 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.